Log In
BCIQ
Print this Print this
 

Factor VII UsiRNA formulated in a DiLA2 lipid-based delivery vehicle

  Manage Alerts
Collapse Summary General Information
Company Marina Biotech Inc.
DescriptionDuplex short interfering RNAs (siRNAs) modified with unlocked nucleobase analogs (UNA) formulated in a DiLA2 liposome formulation targeting Factor VII
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationLiver disease
Indication DetailsTreat liver disease
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$11.1M

$1.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/15/2016

$11.1M

$1.0M

0

Get a free BioCentury trial today